Development of Cell Therapy Technologies Through Joint Research with Universities and Companies
First written in FY2024. 1 of 3 entries say "Advanced", first in FY2025. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「In joint research with the Group for Personalized Cancer Immunotherapy at the Mie University Graduate School of Medicine, we advanced organizational development and other preparations for manufacturing investigational products for a physician-initiated clinical trial of GD2-targeted CAR-T cell therapy for triple-negative breast cancer. The investigational products are scheduled to be manufactured in the next fiscal year.」
We continue to develop the framework and preparations for manufacturing investigational products for GD2-targeted CAR-T cell therapy, with manufacturing scheduled for the next fiscal year. - FY2025AdvancedAnnual report
「We are preparing for the manufacture of investigational products for a physician-initiated clinical trial using GD2-targeted CAR-T cells against triple-negative breast cancer, developed by the Group for Personalized Cancer Immunotherapy at the Mie University Graduate School of Medicine.」
The joint research with Mie University and others has progressed to the preparation stage for manufacturing investigational products for a physician-initiated clinical trial of GD2-targeted CAR-T cells for triple-negative breast cancer. - FY2024First statedAnnual report
「We are conducting research to establish foundational technologies for a method of preparing GD2 GITRL CAR-T cells targeting solid tumors, developed at Mie University, and for a quality control system.」
We continue to conduct joint research with Mie University and T-Cell Nouveau Co., Ltd.